Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals is a global commercial-stage biotechnology company that develops innovative vaccines. Self-described to be committed to improving health worldwide.

Clover Biopharmaceuticals

Clover Biopharmaceuticals | 7,293 followers on LinkedIn. Unleashing the power of innovative vaccines to save lives and improve health around the world | Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals

Jeff Farrow

Senior Director Clinical Operation at Clover Biopharmaceuticals

Aurore Dujardin

Founder， Chairman of the Board of Clover Biopharmaceuticals

Peng Liang

Building Around Talent

Oscar Shen

Attend Europe’s Largest Vaccine R&D Conference！ ☘️☘️☘️ WE ARE ATTENDING AND PRESENTING! ☘️☘️☘️ 📍WORLD VACCINE CONGRESS MEET YOU THERE! #WVC #CLOVER #Vaccine #RSV

msh id	COM:CLOVERBIOPHARMA
symbol	2.2K
name	Clover Biopharmaceuticals, Ltd.
homepage url	https://www.cloverbiopharma.com
country	CN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	387
crunchbase url	-
linkedin url	-
founders	-

market cap	53.43M
enterprise value	-
stage	Post-IPO Equity
raised capital	36.9M
valuation	-

monthly webtraffic	3.49K
monthly webtraffic growth	0.41
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.75
growth cost of revenue	2.6
growth depreciation and amortization	-0.52
growth ebitda	-0.08
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.76
growth gross profit	-2.52
growth gross profit ratio	-

2197

COM:CLOVERBIOPHARMA

Clover Biopharmaceuticals

Last Close

0.30

21/11 07:54

Market Cap

415.27M

Beta: -

Volume Today

677K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	449.16M
cost of revenue	449.16M
depreciation and amortization	4.01M
ebitda	-356.66M
ebitda ratio	-65.74
eps	-0.02
eps diluted	-0.02
operating expenses	212.47M
operating income	-360.67M
operating income ratio	-66.47

accounts receivables	-
capital expenditure	-
cash at beginning of period	222.17M
cash at end of period	222.17M
inventory	96.33M
working capital ttm	1.56B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-